Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Fibrosis, and Acute Kidney Injury Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IGFBP7 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IGFBP7 Recombinant Protein High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. HEK293 expressed for native glycosylation. |
View IGFBP7 Products |
| Gene Delivery | IGFBP7 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and expression validation. |
View IGFBP7 Products |
| Benchmark Ab | Anti-IGFBP7 Benchmark Antibody Recombinant positive control derived from clinical-stage antibody sequences. |
View IGFBP7 Products |
| Validator | IGFBP7 siRNA Set Target-specific knockdown verification in functional cell-based assays. |
View IGFBP7 Products |
| Related Target A | TIMP2 Synergistic biomarker partner; co-elevation of TIMP2 and IGFBP7 indicates acute kidney injury (AKI) risk. |
View TIMP2 Products |
| Related Target B | IGF1 Primary biological partner; IGFBP7 modulates IGF1R signaling pathway activation. |
View IGF1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Cyno/Mouse Evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Subfamily Off-target Screening | Homolog panel (IGFBP1-6) proteins strictly verified by mass spectrometry to avoid cross-reactivity. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives | Sequence-verified siRNA included for target knockdown and specificity validation. |
Live IGFBP7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IGFBP7 therapeutics is intensifying, with major players shifting focus from traditional diagnostics to targeting IGFBP7-mediated microenvironment remodeling. As first-generation diagnostic biomarkers (such as the FDA-cleared NephroCheck assay) reach mature clinical adoption, the next wave of R&D is targeting IGFBP7 as a therapeutic node to overcome immunotherapy resistance in oncology and halt tissue remodeling in fibrotic diseases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Academic Institutes, Biotech Startups | Solid Tumors, Fibrosis | Affinity & Blocking Assay (Need high-purity HEK293-expressed IGFBP7) |
| Diagnostic ELISA / IVD | Astute Medical, Ortho Clinical Diagnostics | Acute Kidney Injury (AKI) | Matched Antibody Pairs & High-stability Recombinant Antigens |
| Combination Therapy (with Anti-PD-1) | Oncology Consortia | Immunotherapy-resistant Tumors | In vitro cell-based functional validation (Need Lentivirus for stable cell lines) |